Suppr超能文献

从 Juniperus excelsa 的根际土壤中放线菌的多样性和生物活性潜力。

Diversity and bioactive potential of Actinomycetia from the rhizosphere soil of Juniperus excelsa.

机构信息

Department of Genetics and Biotechnology, Ivan Franko National University of Lviv, Lviv, 79005, Ukraine.

Department of Pharmaceutical Biotechnology, Saarland University, Saarbruecken, 66123, Germany.

出版信息

Folia Microbiol (Praha). 2023 Aug;68(4):645-653. doi: 10.1007/s12223-023-01047-x. Epub 2023 Mar 22.

Abstract

Microbial natural products are among the main sources of compounds used in the medical biotechnology field for the purpose of drug development. However, as antibiotic resistance in pathogenic microorganisms is known to be increasing dramatically, there exists a need to develop new antibiotics. Actinomycetia have proven to be a good source of biologically active compounds, although the rediscovery of previously known compounds significantly slows down the introduction of new antibiotics. As a consequence, increasing attention is being paid to the isolation of actinomycete strains from previously unexplored sources, which can significantly increase the likelihood of discovering new biologically active compounds. This study investigated the diversity and bioactive potential of 372 actinomycete strains isolated from the rhizosphere soil of Juniperus excelsa M. Bieb. The examined actinomycete strains belonged to 11 genera, namely, Actinoplanes, Actinorectispora, Amycolatopsis, Kribbella, Micrococcus, Micromonospora, Nocardia, Promicromonospora, Rhodococcus, Saccharopolyspora and Streptomyces. The bioactive potential of each isolated actinomycete strain was determined on the basis of its ability to produce antimicrobial metabolites against Gram-positive and Gram-negative bacteria and yeast. Some 159 strains (42.74%) exhibited antimicrobial activity against at least one of the tested microbial strains. The dereplication analysis of the extract of the Streptomyces sp. Je 1-651 strain, which exhibited strong antimicrobial activity, led to the annotation of spiramycins and stambomycins. Moreover, the phylogenetic analysis based on the 16S rRNA gene sequence of the Je 1-651 strain revealed it to be close to the S. ambofaciens.

摘要

微生物天然产物是用于药物开发的医学生物技术领域化合物的主要来源之一。然而,由于致病性微生物的抗生素耐药性众所周知正在急剧增加,因此需要开发新的抗生素。放线菌已被证明是生物活性化合物的良好来源,尽管重新发现以前已知的化合物会显著减缓新抗生素的引入。因此,人们越来越关注从以前未开发的来源中分离放线菌菌株,这可以显著增加发现新的生物活性化合物的可能性。本研究调查了从 Juniperus excelsa M. Bieb 的根际土壤中分离的 372 株放线菌菌株的多样性和生物活性潜力。所研究的放线菌菌株属于 11 个属,即放线菌属、放线菌素属、Amycolatopsis、Kribbella、微球菌属、密旋菌属、诺卡氏菌属、普洛米先斯菌属、红球菌属、糖多孢菌属和链霉菌属。根据每个分离的放线菌菌株产生抗革兰氏阳性和革兰氏阴性细菌和酵母的抗菌代谢物的能力来确定其生物活性潜力。约 159 株(42.74%)对至少一种测试的微生物菌株表现出抗菌活性。对表现出强抗菌活性的链霉菌属 Je 1-651 菌株提取物的去重复分析导致了螺旋霉素和 Stam bomycins 的注释。此外,基于 Je 1-651 菌株的 16S rRNA 基因序列的系统发育分析表明,它与 S. ambofaciens 密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12ce/10031196/1c00b7c06733/12223_2023_1047_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验